

Dammeijer & de Gooijer et al. - Table S1

		Immune monitoring subgroup			Total cohort NVALT19 study	
		Gemcitabine (n=27)	BSC (n=19)	Total (n=46)	Gemcitabine (n=65)	BSC (n=65)
		Number, %	Number, %	Number	Number, %	Number, %
Sex						
	Female	3 (11)	4 (21)	39	7 (11)	11 (17)
	Male	24 (89)	15 (79)	7	58 (89)	54 (83)
Age						
	Median (years)	68	70	68	69	69
	Range	43-79	57-80	43-80	43-84	35-82
WHO performance score						
	0	16 (59)	10 (53)	26 (57)	37 (57)	38 (58)
	1	11 (41)	8 (42)	19 (41)	27 (42)	25 (38)
	2	0	1 (5)	1	0	2 (3)
Histological subtype						
	Epithelial	24 (89)	17 (89)	41 (89)	57 (88)	57 (88)*
	Biphasic	3 (11)	2 (11)	5 (11)	5 (8)	6 (9)
	Sarcomatoid	0	0	0	3 (4)	2 (3)
Best response to first-line treatment						
	Complete response	2 (7)	0	2 (4)	2 (3)	1 (2)
	Partial response	6 (22)	7 (37)	13 (28)	25 (38)	26 (40)
	Stable disease	19 (70)	12 (63)	31 (67)	38 (58)	38 (58)
Tumor stage						
	Stages I-II	14 (52)	11 (58)	25 (54)	31 (48)	30 (46)
	Stages III-IV	9 (33)	27 (42%)	12 (26)	25 (39)	27 (42)
	Unknown	4 (15)	5 (26)	9 (20)	9 (14)	8 (12)
WHO; World Health Organization. *While on study, the diagnosis of one patient was changed into another malignancy.						